Madopar (Benserazide, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter lacking in Parkinson's disease. Benserazide inhibits the peripheral enzyme that would otherwise convert levodopa outside the brain, ensuring more levodopa reaches the central nervous system for effective dopamine synthesis.

The dosage of Madopar is individualized and set by the prescribing clinician based on the patient’s disease stage, response, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

The safety of Madopar in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Madopar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Madopar combines levodopa with benserazide, offering higher central availability of levodopa compared with levodopa alone. Compared with dopamine agonists, it provides more consistent symptom control but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors.

Madopar should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date indicated on the label.

Madopar is taken orally, usually with a small amount of food to reduce gastrointestinal upset. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include the development of dyskinesia (involuntary movements), severe hypotension, neuroleptic malignant syndrome, and rare psychiatric disturbances such as hallucinations. Patients should be monitored regularly, and any sudden or severe symptoms should be reported to a healthcare provider promptly.

Madopar is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients in the formulation. It should also be avoided in individuals taking non‑selective MAO inhibitors or those with narrow‑angle glaucoma, unless specifically directed by a physician.